Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.05
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 +1.91%
Revenue Growth %: -15.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -15.8%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $15.5 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
